Krystal Biotech Stock Soars After FDA Label Expansion for VYJUVEK
Krystal Biotech's stock experienced a significant surge after the FDA expanded the label for its product VYJUVEK. This development is anticipated to enhance market potential and investor confidence. Additionally, TD Cowen has maintained a Buy rating on the stock, further reflecting optimism about the company's future prospects.
Krystal Biotech Stock Soars After FDA Label Expansion for VYJUVEK
Krystal Biotech's stock experienced a significant surge after the FDA expanded the label for its product VYJUVEK. This development is anticipated to enhance market potential and investor confidence. Additionally, TD Cowen has maintained a Buy rating on the stock, further reflecting optimism about the company's future prospects.
Why World Pulse Now
Global Coverage
All major sources, one page
Emotional Lens
Feel the mood behind headlines
Trending Stories
Know what’s trending, globally
Read Less, Know More
Get summaries. Save time
Multi-Language
Switch languages to read your way
Save for Later
Your stories, stored for later
Live Stats
Our system has analyzed 4,441 articles worldwide
~185 per hour
431 trending stories shaping headlines
From breaking news to viral moments
Monitoring 200 trusted sources
Major outlets & specialized publications
Latest update an hour ago
Always fresh